Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivesto ABLTS:0N4A 24 Net Current Asset Value is kr1.37 as of Jun. 2026. GuruFocus rates LTS:0N4A with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 604 Drug Manufacturers companies, Vivesto AB ranks worse than 53.97% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Vivesto AB's net current asset value per share for the quarter that ended in Jun. 2026 was kr1.37.
The historical rank and industry rank for Vivesto AB's Net Current Asset Value or its related term are showing as below:
LTS:0N4A'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.47 Med: 4.29 Max: 14.09
Current: 6.57
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Vivesto AB was 14.09. The lowest was 1.47. And the median was 4.29.
LTS:0N4A's Price-to-Net-Current-Asset-Value is ranked worse than 53.97% of 604
companies
in the Drug Manufacturers industry
Industry Median: 6
vs LTS:0N4A: 6.57
Vivesto AB (LTS:0N4A) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Vivesto AB Net Current Asset Value Related Terms
Vivesto AB Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Vivesto AB's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0N4A vs ZTS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vivesto AB's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivesto AB Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivesto AB's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Vivesto AB's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of kr1.37 mean?
Vivesto AB (LTS:0N4A) has a Net Current Asset Value of kr1.37 as of Jun. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Vivesto AB and its competitors. According to the industry distribution chart, Vivesto AB ranks #326 out of 604 companies in the Drug Manufacturers industry, placing it in the top 54%.
Is Vivesto AB's Net Current Asset Value too high?
Vivesto AB's current Net Current Asset Value is kr1.37. Based on the distribution chart, Vivesto AB ranks #326 out of 604 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vivesto AB has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Vivesto AB's Net Current Asset Value compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vivesto AB ranks #326 out of 604 companies for Net Current Asset Value. This places Vivesto AB in the lower half of its industry. The industry median Net Current Asset Value is 6.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 6.00, based on 604 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Vivesto AB and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 6.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivesto AB's current Net Current Asset Value is kr1.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivesto AB stock overvalued right now?
Vivesto AB (LTS:0N4A) has a current Net Current Asset Value of kr1.37. The current Net Current Asset Value is kr1.37. Vivesto AB's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Vivesto AB (LTS:0N4A), the current Net Current Asset Value is kr1.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivesto AB is a research and development company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company's product development leverages its proprietary technology platforms to manufacture novel drug formulations that are intended to demonstrate improved properties in comparison with current alternatives, which can lead to a reduced side-effect profile and an expanded therapeutic area. The company has a portfolio of projects targeting cancer treatments.
24GF Score
Get the complete analysis for LTS:0N4A
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0N4A has been successfully added to your 
